Clinical trials: Fibrotic Interstitial Lung Disease
Usual Interstitial Pneumonia, Nonspecific Interstitial Pneumonia
Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias
The diagnosis of idiopathic interstitial pneumonia (IIP) is based on computed tomography (CT) imaging, whereas lung function studies are used for staging and follow up.
- Trial name
- Dm&Vc (NCT02596841)
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Idiopathic Pulmonary Fibrosis
Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes
Two oral medications, nintedanib and pirfenidone, were approved simultaneously by the FDA in October 2014 for the treatment of this disease.
- Trial name
- IPF-LTOS (NCT04316780)
- Testing
- Retrospective observational study- no intervention to occur.
- Where
- 8 sites in United States
- Volunteers
- 320 people
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Sarcoidosis, Pulmonary
RCT of Nintedanib in Fibrotic Sarcoidosis
Sarcoidosis is generally managed with outdoor immune modulatory drugs, most commonly oral steroids and at times drugs like methotrexate or azathioprine as a steroid sparing agent.
- Trial name
- NINSARC (NCT06479603)
- Testing
- Nintedanib, Standard of care
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Interstitial Lung Disease (ILD)
Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China
This project aimed to: 1) construct a cohort of no less than 10000 cases of f-ILD (including pneumoconiosis ≥3000 cases) with continuous regular follow-up to reveal the clinical phenotypes closely related to the development…
- Trial name
- NCT06655090
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Dai Huaping
Fibrotic Interstitial Lung Disease
Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease
Our study aims to investigate the benefits of an outpatient pulmonary rehabilitation program in a population of subjects with fibrotic interstitial lung disease.
- Trial name
- NCT00415272
- Testing
- Pulmonary Rehabilitation
- Where
- United States
- Sponsor
- University of California, San Francisco
Pulmonary Fibrosis
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation…
- Trial name
- ILDnose (NCT04680832)
- Testing
- Electronic nose
- Where
- 5 sites in Australia, France and 3 more
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
IPF, Fibrotic Lung Disease
Prognostic Score Comparison in IPF and HP
The goal of this retrospective observational study is to evaluate and compare the prognostic value of GAP, ILD-GAP, and CPI scoring systems in patients diagnosed with interstitial lung diseases (ILDs), specifically Idiopathic…
- Conditions
- IPF, Fibrotic Lung Disease, Hypersensitivity Pneumonitis, Interstitial Lung Disease (ILD)
- Trial name
- NCT07169253
- Testing
- GAP Index, ILD-GAP Index, Composite Physiologic Index (CPI)
- Where
- Turkey (Türkiye)
- Volunteers
- 143 people
- Sponsor
- Saglik Bilimleri Universitesi
Idiopathic Pulmonary Fibrosis
Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden
The objective of the current research project is, by using high quality Swedish registry data, to evaluate use, tolerance and effect of anti-fibrotic drugs in IPF-patients.
- Trial name
- NCT04019080
- Testing
- Anti-fibrostic drugs
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Karolinska University Hospital